ranibizumab intravitreal injection
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy
Conditions
Polypoidal Choroidal Vasculopathy
Trial Timeline
Jan 1, 2007 → Sep 1, 2010
NCT ID
NCT00424710About ranibizumab intravitreal injection
ranibizumab intravitreal injection is a phase 1 stage product being developed by Pacific Biosciences for Polypoidal Choroidal Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00424710. Target conditions include Polypoidal Choroidal Vasculopathy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00424710 | Phase 1 | Completed |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept Intravitreous Injection | Bayer | Approved | 82 |
| aflibercept 8 mg | Bayer | Phase 3 | 74 |
| aflibercept | Bayer | Approved | 82 |